Clinical Trial

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

Recruiting
View on ClinicalTrials.gov →
Summary
Study on the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-NY104 PET/CT in diagnosing primary, recurrent, and metastatic lesions of renal cell carcinoma; and investigate the effect of oral low-dose CAIX inhibitor (Acetazolamide) on the tissue distribution of 18F-NY104 in renal cell carcinoma patients, particularly in the stomach and kidneys.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-01.
Trial Details
NCT Number NCT06916624
Lead Sponsor The Affiliated Hospital of Qingdao University
Collaborators: Qianfoshan Hospital, Weifang People's Hospital, Zibo Central Hospital, Jining Medical University
Conditions Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC)
Enrollment 40 participants
Start Date 2025-04-12
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-29